Promoter-Dependent Mechanism Leading to Selective Hypomethylation within the 5′ Region of Gene MAGE-A1 in Tumor Cells

REFERENCES

• Antequera, F., Boyes J., and Bird A.. 1990. High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell 62:503–514.
   PubMedGoogle Scholar
• Baylin, S. B., Herman J. G., Graff J. R., Vertino P. M., and Issa J. P.. 1998. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 72:141–196.
   PubMed Web of Science ®Google Scholar
• Bird, A. 2002. DNA methylation patterns and epigenetic memory. Genes Dev. 16:6–21.
   PubMed Web of Science ®Google Scholar
• Brandeis, M., Frank D., Keshet I., Siegfried Z., Mendelsohn M., Nemes A., Temper V., Razin A., and Cedar H.. 1994. Sp1 elements protect a CpG island from de novo methylation. Nature 371:435–438.
   PubMed Web of Science ®Google Scholar
• Brasseur, F., Rimoldi D., Lienard D., Lethe B., Carrel S., Arienti F., Suter L., Vanwijck R., Bourlond A., Humblet Y., et al. 1995. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int. J. Cancer 63:375–380.
   PubMed Web of Science ®Google Scholar
• Chesnokov, I. N., and Schmid C. W.. 1995. Specific Alu binding protein from human sperm chromatin prevents DNA methylation. J. Biol. Chem. 270:18539–18542.
   PubMedGoogle Scholar
• Coral, S., Sigalotti L., Altomonte M., Engelsberg A., Colizzi F., Cattarossi I., Maraskovsky E., Jager E., Seliger B., and Maio M.. 2002. 5-aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res. 8:2690–2695.
   PubMed Web of Science ®Google Scholar
• Costello, J. F., Fruhwald M. C., Smiraglia D. J., Rush L. J., Robertson G. P., Gao X., Wright F. A., Feramisco J. D., Peltomaki P., Lang J. C., Schuller D. E., Yu L., Bloomfield C. D., Caligiuri M. A., Yates A., Nishikawa R., Su Huang H., Petrelli N. J., Zhang X., O'Dorisio M. S., Held W. A., Cavenee W. K., and Plass C.. 2000. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 24:132–138.
   PubMed Web of Science ®Google Scholar
• Daniels, R., Lowell S., Bolton V., and Monk M.. 1997. Transcription of tissue-specific genes in human preimplantation embryos. Hum. Reprod. 12:2251–2256.
   PubMed Web of Science ®Google Scholar
• De Plaen, E., Arden K., Traversari C., Gaforio J. J., Szikora J. P., De Smet C., Brasseur F., van der Bruggen P., Lethe B., Lurquin C., et al. 1994. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40:360–369.
   PubMed Web of Science ®Google Scholar
• De Smet, C., Courtois S. J., Faraoni I., Lurquin C., Szikora J. P., De Backer O., and Boon T.. 1995. Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene. Immunogenetics 42:282–290.
   PubMed Web of Science ®Google Scholar
• De Smet, C., De Backer O., Faraoni I., Lurquin C., Brasseur F., and Boon T.. 1996. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl. Acad. Sci. USA 93:7149–7153.
   PubMed Web of Science ®Google Scholar
• De Smet, C., Lurquin C., Lethe B., Martelange V., and Boon T.. 1999. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol. Cell. Biol. 19:7327–7335.
   PubMed Web of Science ®Google Scholar
• De Smet, C., Lurquin C., van der Bruggen P., De Plaen E., Brasseur F., and Boon T.. 1994. Sequence and expression pattern of the human MAGE2 gene. Immunogenetics 39:121–129.
   PubMedGoogle Scholar
• Ehrlich, M. 2002. DNA methylation in cancer: too much, but also too little. Oncogene 21:5400–5413.
   PubMed Web of Science ®Google Scholar
• Ehrlich, M., Jiang G., Fiala E., Dome J. S., Yu M. C., Long T. I., Youn B., Sohn O. S., Widschwendter M., Tomlinson G. E., Chintagumpala M., Champagne M., Parham D., Liang G., Malik K., and Laird P. W.. 2002. Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene 21:6694–6702.
   PubMed Web of Science ®Google Scholar
• Feinberg, A. P., and Tycko B.. 2004. The history of cancer epigenetics. Nat. Rev. Cancer 4:143–153.
   PubMed Web of Science ®Google Scholar
• Feinberg, A. P., and Vogelstein B.. 1983. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301:89–92.
   PubMed Web of Science ®Google Scholar
• Feinberg, A. P., and Vogelstein B.. 1983. Hypomethylation of ras oncogenes in primary human cancers. Biochem. Biophys. Res. Commun. 111:47–54.
   PubMed Web of Science ®Google Scholar
• Ferguson-Smith, A. C., and Surani M. A.. 2001. Imprinting and the epigenetic asymmetry between parental genomes. Science 293:1086–1089.
   PubMed Web of Science ®Google Scholar
• Gama-Sosa, M. A., Slagel V. A., Trewyn R. W., Oxenhandler R., Kuo K. C., Gehrke C. W., and Ehrlich M.. 1983. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 11:6883–6894.
   PubMed Web of Science ®Google Scholar
• Gaudet, F., Hodgson J. G., Eden A., Jackson-Grusby L., Dausman J., Gray J. W., Leonhardt H., and Jaenisch R.. 2003. Induction of tumors in mice by genomic hypomethylation. Science 300:489–492.
   PubMed Web of Science ®Google Scholar
• Hellmann-Blumberg, U., Hintz M. F., Gatewood J. M., and Schmid C. W.. 1993. Developmental differences in methylation of human Alu repeats. Mol. Cell Biol. 13:4523–4530.
   PubMed Web of Science ®Google Scholar
• Jackson-Grusby, L., Beard C., Possemato R., Tudor M., Fambrough D., Csankovszki G., Dausman J., Lee P., Wilson C., Lander E., and Jaenisch R.. 2001. Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation. Nat. Genet. 27:31–39.
   PubMed Web of Science ®Google Scholar
• Janssen, B. L., van de Locht L. T., Fourkour A., de Smet C., Mensink E. J., van Muijen G. N., and de Vries T. J.. 1999. Transcription of the MAGE-1 gene and the methylation status of its Ets binding promoter elements: a quantitative analysis in melanoma cell lines using a real-time polymerase chain reaction technique. Melanoma Res. 9:213–222.
   PubMedGoogle Scholar
• Kafri, T., Ariel M., Brandeis M., Shemer R., Urven L., McCarrey J., Cedar H., and Razin A.. 1992. Developmental pattern of gene-specific DNA methylation in the mouse embryo and germ line. Genes Dev. 6:705–714.
   PubMed Web of Science ®Google Scholar
• Kirillov, A., Kistler B., Mostoslavsky R., Cedar H., Wirth T., and Bergman Y.. 1996. A role for nuclear NF-kappaB in B-cell-specific demethylation of the Igκ locus. Nat. Genet. 13:435–441.
   PubMed Web of Science ®Google Scholar
• Lin, I. G., Tomzynski T. J., Ou Q., and Hsieh C. L.. 2000. Modulation of DNA binding protein affinity directly affects target site demethylation. Mol. Cell. Biol. 20:2343–2349.
   PubMedGoogle Scholar
• Loriot, A., Boon T., and De Smet C.. 2003. Five new human cancer-germline genes identified among 12 genes expressed in spermatogonia. Int. J. Cancer 105:371–376.
   PubMedGoogle Scholar
• Lukyanov, D. V., Urusova M. E., Shcherba K. M., and Podgornaya O. I.. 2000. Alu-DNA repeat-binding protein p68 is a part of Alu-RNA containing alpha-RNP. Eur. J. Biochem. 267:2362–2371.
   PubMedGoogle Scholar
• Macleod, D., Ali R. R., and Bird A.. 1998. An alternative promoter in the mouse major histocompatibility complex class II I-Aβ gene: implications for the origin of CpG islands. Mol. Cell. Biol. 18:4433–4443.
   PubMedGoogle Scholar
• Macleod, D., Charlton J., Mullins J., and Bird A. P.. 1994. Sp1 sites in the mouse aprt gene promoter are required to prevent methylation of the CpG island. Genes Dev. 8:2282–2292.
   PubMed Web of Science ®Google Scholar
• Monk, M., Boubelik M., and Lehnert S.. 1987. Temporal and regional changes in DNA methylation in the embryonic, extraembryonic and germ cell lineages during mouse embryo development. Development 99:371–382.
   PubMed Web of Science ®Google Scholar
• Mutskov, V. J., Farrell C. M., Wade P. A., Wolffe A. P., and Felsenfeld G.. 2002. The barrier function of an insulator couples high histone acetylation levels with specific protection of promoter DNA from methylation. Genes Dev. 16:1540–1554.
   PubMedGoogle Scholar
• Narayan, A., Ji W., Zhang X. Y., Marrogi A., Graff J. R., Baylin S. B., and Ehrlich M.. 1998. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int. J. Cancer 77:833–838.
   PubMed Web of Science ®Google Scholar
• Pfeifer, G. P., Steigerwald S. D., Hansen R. S., Gartler S. M., and Riggs A. D.. 1990. Polymerase chain reaction-aided genomic sequencing of an X chromosome-linked CpG island: methylation patterns suggest clonal inheritance, CpG site autonomy, and an explanation of activity state stability. Proc. Natl. Acad. Sci. USA 87:8252–8256.
   PubMed Web of Science ®Google Scholar
• Riggs, A. D., and Pfeifer G. P.. 1992. X-chromosome inactivation and cell memory. Trends Genet. 8:169–174.
   PubMedGoogle Scholar
• Sahin, U., Tureci O., Chen Y. T., Seitz G., Villena-Heinsen C., Old L. J., and Pfreundschuh M.. 1998. Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. Int. J. Cancer 78:387–389.
   PubMed Web of Science ®Google Scholar
• Tamaru, H., and Selker E. U.. 2001. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature 414:277–283.
   PubMed Web of Science ®Google Scholar
• Traversari, C., van der Bruggen P., Van den Eynde B., Hainaut P., Lemoine C., Ohta N., Old L., and Boon T.. 1992. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 35:145–152.
   PubMedGoogle Scholar
• van Baren, N., Brasseur F., Godelaine D., Hames G., Ferrant A., Lehmann F., Andre M., Ravoet C., Doyen C., Spagnoli G. C., Bakkus M., Thielemans K., and Boon T.. 1999. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 94:1156–1164.
   PubMed Web of Science ®Google Scholar
• Van Der Bruggen, P., Zhang Y., Chaux P., Stroobant V., Panichelli C., Schultz E. S., Chapiro J., Van Den Eynde B. J., Brasseur F., and Boon T.. 2002. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 188:51–64.
   PubMed Web of Science ®Google Scholar
• Weber, J., Salgaller M., Samid D., Johnson B., Herlyn M., Lassam N., Treisman J., and Rosenberg S. A.. 1994. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine. Cancer Res. 54:1766–1771.
   PubMed Web of Science ®Google Scholar
• Weiser, T. S., Guo Z. S., Ohnmacht G. A., Parkhurst M. L., Tong-On P., Marincola F. M., Fischette M. R., Yu X., Chen G. A., Hong J. A., Stewart J. H., Nguyen D. M., Rosenberg S. A., and Schrump D. S.. 2001. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J. Immunother. 24:151–161.
   PubMed Web of Science ®Google Scholar
• Yoder, J. A., Walsh C. P., and Bestor T. H.. 1997. Cytosine methylation and the ecology of intragenomic parasites. Trends Genet. 13:335–340.
   PubMed Web of Science ®Google Scholar